Health TrialsbyHealthPanel

Brief Crisis Therapy for Suicidal Children and Adolescents

ConditionsSuicidal IdeationSuicidal Behavior
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-18
SponsorTel Aviv University

About this trial

The goal of this clinical trial is to learn if the Ultra-Brief Interpersonal Psychotherapy for Adolescents with Suicidal Ideation (IPT-A-SCI) works to reduce suicidal thoughts and behaviors in children and adolescents. The study will also examine whether treatment effects continue after treatment ends and whether some participants benefit more from the intervention than others. The main questions it aims to answer are:

Does IPT-A-SCI reduce suicidal thoughts and behaviors in children and adolescents? Do the effects of IPT-A-SCI continue three months after treatment ends? Do some children and adolescents benefit more from IPT-A-SCI than others?

Participants will:

Receive IPT-A-SCI treatment consisting of five weekly sessions Complete questionnaires before treatment, during treatment, at the end of treatment, and three months after treatment ends Have their parents complete questionnaires at the same time points

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Children and adolescents aged 8-18 years presenting with suicidal ideation or behavior

Suicide risk assessment indicating suitability for outpatient treatment,

Fluency in Hebrew

Ability to attend five weekly treatment sessions

Disqualifiers

Acute medical or psychiatric condition requiring immediate inpatient treatment

Linguistic, developmental, neurological, or intellectual limitations that prevent understanding of the treatment protocol or study procedures

Inability to participate in outpatient psychotherapy

Trial design

Design model

Single group

Treatments tested in this trial

  • IPT-A-SCI

    Behavioral

    Manualized ultra-brief interpersonal psychotherapy intervention combined with safety planning for children and adolescents with suicidal ideation or behavior.

Treatment groups

120 Participants
are divided into 1 treatment group
Group A: IPT-A-SCIExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in Severity of Suicidal Ideation

Change in severity of suicidal ideation and behavior assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). The C-SSRS assesses the severity of suicidal ideation and the occurrence of suicidal behaviors. The suicidal ideation severity score ranges from 1 to 5, with higher scores indicating greater severity of suicidal ideation.

Time frame
Baseline to 3-month follow-up

Secondary outcomes

1

Change in Intensity of Suicidal Ideation

Change in intensity of suicidal ideation assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS) ideation intensity scale. The C-SSRS assesses the intensity of the most severe suicidal ideation endorsed by evaluating five dimensions: frequency, duration, controllability, deterrents, and reasons for ideation. Total scores range from 0 to 25, with a score of 0 assigned when no suicidal ideation is endorsed and scores from 2 to 25 indicating increasing intensity of suicidal ideation. Higher scores indicate more intense suicidal ideation and a worse outcome.

Time frame
Baseline to 3-month follow-up
2

Change in Depressive Symptoms

Change in depressive symptoms assessed using the Short Mood and Feelings Questionnaire (SMFQ). Scores range from 0 to 26, with higher scores indicating greater depressive symptom severity and a worse outcome.

Time frame
Baseline to 3-month follow-up
3

Change in Perceived Social Support

Change in perceived social support assessed using the Multidimensional Scale of Perceived Social Support (MSPSS). Scores range from 12 to 84, with higher scores indicating greater perceived social support and a better outcome.

Time frame
Baseline to 3-month follow-up
4

Change in Emotional Processing (Alexithymia)

Change in emotional processing and alexithymia assessed using the Toronto Alexithymia Scale (TAS-20). Scores range from 20 to 100, with higher scores indicating greater difficulty identifying and describing emotions (greater alexithymia) and a worse outcome.

Time frame
Baseline to 3-month follow-up

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Tel Aviv University

Lead sponsor

Geha Mental Health Center

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: